(Reuters) – The U.S. Food and Drug Administration on Wednesday approved Regeneron Pharmaceuticals’ Inmazeb as the first FDA-approved treatment for the Ebola virus infection in adults and children.
Inmazeb, a mixture of three monoclonal antibodies, was tested in 382 adults and children with confirmed Zaire ebolavirus infection in a clinical trial, the health regulator said.
(Reporting by Vishwadha Chander in Bengaluru; Editing by Shinjini Ganguli)
